CB-5083: Redefining p97 Inhibition for Protein and Lipid Homeostasis Research

Introduction

Cellular homeostasis depends on tightly regulated protein quality control and lipid metabolic pathways, with the AAA-ATPase p97 (also known as valosin-containing protein, VCP) at the intersection of these processes. The development of CB-5083, a potent, selective, and orally bioavailable p97 inhibitor, has provided researchers with a powerful tool to dissect the molecular mechanisms underlying protein degradation, unfolded protein response (UPR), and the regulation of endoplasmic reticulum (ER) lipid synthesis. While previous literature has highlighted CB-5083’s role in disrupting protein homeostasis and inducing apoptosis in cancer cells, this article uniquely synthesizes current research on the interplay between p97 inhibition, ER protein quality control, and lipid metabolic pathways, offering new perspectives for cancer biology, metabolic research, and therapeutic innovation.

The Central Role of p97 in Cellular Homeostasis

p97 AAA-ATPase: Master Orchestrator of Protein Degradation

The p97 AAA-ATPase is a highly conserved molecular machine involved in diverse cellular functions, including organelle membrane fusion, endosomal cargo sorting, and, most critically, the ER-associated degradation (ERAD) pathway. p97 drives the extraction of misfolded or dysfunctional proteins from the ER membrane, enabling their subsequent proteasomal degradation. This process is essential for maintaining proteostasis and preventing the toxic accumulation of poly-ubiquitinated proteins (Carrasquillo Rodríguez et al., 2024).

ER Protein Quality Control, UPR, and Lipid Synthesis: An Emerging Nexus

Recent advances have illuminated the tight coupling between protein quality control mechanisms (such as ERAD and UPR) and ER lipid metabolic processes. The ER is the hub for both protein folding and de novo synthesis of membrane and storage lipids. Disruptions in protein homeostasis, often sensed and mediated via p97 and the UPR, can lead to secondary effects on lipid synthesis and ER membrane dynamics, as demonstrated in the regulation of enzymes like lipin 1 by the CTDNEP1-NEP1R1 complex (Carrasquillo Rodríguez et al., 2024).

Mechanism of Action of CB-5083: Selective p97 AAA-ATPase Inhibition

Biochemical Properties and Selectivity

CB-5083 is a rationally designed small molecule that selectively targets the second ATPase domain (D2) of p97, competing with ATP at its binding site. With an IC50 of 15.4 nM against wild-type p97, CB-5083 exhibits high potency and specificity, minimizing off-target effects on related AAA-ATPases. Its chemical formula is C24H23N5O2, with a molecular weight of 413.47, and it is formulated for optimal solubility in DMSO and ethanol, but not in water.

Disrupting the Protein Degradation Pathway

By inhibiting p97, CB-5083 blocks the extraction and proteasomal degradation of poly-ubiquitinated proteins. This blockade leads to the accumulation of misfolded proteins within the ER, triggering ER stress and activation of the unfolded protein response (UPR). Sustained UPR activation, when unresolved, induces apoptotic signaling through pathways such as the caspase cascade, resulting in cancer cell apoptosis induction.

Evidence from In Vitro and In Vivo Studies

CB-5083 has been shown to induce dose-dependent accumulation of TCRα-GFP in the ER and poly-ubiquitinated proteins in multiple cell lines, including HEK293T, A549, and HCT116. In mouse xenograft models of colorectal adenocarcinoma, non-small-cell lung cancer, and multiple myeloma, oral administration of CB-5083 yields significant tumor growth inhibition (TGI up to 63%). These findings underscore the translational potential of CB-5083 as both a research tool and a therapeutic candidate.

CB-5083 and the Unfolded Protein Response: A Molecular Cascade

The unfolded protein response (UPR) is a complex cellular program activated during ER stress, aiming to restore proteostasis by increasing chaperone expression, attenuating protein translation, and enhancing ERAD capacity. Persistent ER stress due to p97 inhibition by CB-5083 can overwhelm these adaptive mechanisms, shifting the balance from survival to apoptosis. This mechanistic link is particularly relevant in cancer cells, which often exhibit heightened proteotoxic stress and are more susceptible to UPR-driven cell death.

Integrating Emerging Insights: CB-5083 as a Probe for ER Lipid Regulation

While prior reviews, such as "CB-5083: Targeting p97 AAA-ATPase to Disrupt Protein Home...", primarily focus on CB-5083's cytotoxic and anti-cancer activities, this article advances the discussion by integrating recent discoveries in ER lipid metabolism. Notably, the reference study by Carrasquillo Rodríguez et al. (2024) reveals that the stability and function of CTDNEP1—a phosphatase regulating ER membrane lipid synthesis—are intricately controlled by its regulatory subunit, NEP1R1, and that this regulation is linked to proteasomal degradation pathways involving p97. By leveraging CB-5083 to inhibit p97, researchers can dissect the crosstalk between protein degradation and lipid biosynthesis, enabling the study of how proteostasis disruption impacts ER membrane dynamics and lipid storage.

Experimental Applications: Beyond Traditional Oncology Research

CB-5083's unique ability to induce both protein homeostasis disruption and perturbations in lipid metabolic pathways positions it as a valuable probe in the following advanced applications:

• Deciphering the role of p97 in ER membrane expansion and lipid droplet formation: By modulating p97 activity with CB-5083, researchers can study how protein degradation intersects with lipid synthesis, as highlighted in the CTDNEP1-NEP1R1-lipin 1 axis (Carrasquillo Rodríguez et al., 2024).
• Exploring metabolic vulnerabilities in cancer cells: Many tumors rely on robust protein and lipid synthesis for rapid proliferation. CB-5083-induced stress can unmask dependencies on UPR and lipid homeostasis, identifying new therapeutic targets.
• Modeling neurodegenerative and metabolic diseases: Given the shared mechanisms of proteostasis and lipid metabolism in diseases such as ALS and hepatic steatosis, CB-5083 serves as a tool to probe pathogenic pathways beyond oncology.

Comparative Analysis: CB-5083 in the Landscape of p97 Inhibitors and Research Tools

Existing articles, such as "CB-5083: A Selective p97 Inhibitor for Protein Homeostasi..." and "CB-5083: Unraveling ER-Associated Protein and Lipid Homeo...", provide comprehensive overviews of CB-5083's mechanistic action and its role as a probe for protein and lipid homeostasis. However, this article differentiates itself by focusing on the integration of CB-5083-mediated p97 inhibition with cutting-edge findings on ER lipid regulation—specifically, the nuanced contribution of the CTDNEP1-NEP1R1 complex and its susceptibility to proteasomal degradation. By referencing the latest molecular biology insights, we provide a framework for using CB-5083 not only as a cytotoxic agent but as a strategic tool for unraveling the molecular interplay between proteostasis and lipid metabolism.

Advantages of CB-5083 Over Alternative Approaches

• Greater specificity and oral bioavailability: Unlike earlier-generation p97 inhibitors, CB-5083 offers higher selectivity and in vivo efficacy, enabling both cell-based and animal studies with translational relevance.
• Suitability for dissecting dynamic cellular responses: The rapid, tunable inhibition afforded by CB-5083 allows for time-resolved studies of protein and lipid turnover, UPR activation, and caspase signaling pathway engagement.
• Integration with multi-omics and imaging readouts: CB-5083 enables researchers to combine proteomics, lipidomics, and advanced microscopy to visualize and quantify the impact of p97 inhibition across cellular compartments.

Best Practices: Handling and Experimental Use of CB-5083

CB-5083 is supplied as a solid and should be stored at -20°C. For experimental solutions, DMSO is recommended at concentrations up to >20.65 mg/mL, with ethanol as an alternative solvent (>4.4 mg/mL). Gentle warming and ultrasonication can enhance solubility. It is not recommended to store solutions long-term; freshly prepared aliquots ensure optimal activity. CB-5083 is intended strictly for research purposes and not for clinical or diagnostic use.

Conclusion and Future Outlook

CB-5083 has redefined the landscape of p97 research, enabling unprecedented insights into the dual regulation of protein and lipid homeostasis. By leveraging its unique selectivity and bioavailability, scientists can now dissect the molecular interplay between ER-associated degradation, UPR, and lipid metabolic pathways, expanding the frontiers of cancer, metabolic, and neurodegenerative disease research. As highlighted in the latest findings (Carrasquillo Rodríguez et al., 2024), the future of p97-targeted studies will increasingly rely on tools like CB-5083 to unravel the complexity of cellular homeostasis and identify new therapeutic strategies.

For detailed product specifications, protocols, and ordering information, visit the CB-5083 product page.